<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68823">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01915940</url>
  </required_header>
  <id_info>
    <org_study_id>FSV5-002</org_study_id>
    <nct_id>NCT01915940</nct_id>
  </id_info>
  <brief_title>VISION5 Product Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the ForSight VISION5 Product as Compared to the Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ForSight Vision5, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ForSight Vision5, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this Phase 2 study is to evaluate whether the VISION5 Product is
      non-inferior to that of timolol ophthalmic solution (0.5%) at 12 weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Ocular Tonometry</measure>
    <time_frame>12 weeks post randomization</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular Tonometry</measure>
    <time_frame>6-months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">126</enrollment>
  <condition>Primary Open-Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>VISION5 Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VISION5 Product in both eyes and placebo drops twice a day in each eye.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Timolol 0.5% + Placebo VISION5 Product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Timolol (timoptic ophthalmic solution 0.5%) twice a day in each eye plus VISION5 Placebo Product</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VISION5 Product</intervention_name>
    <arm_group_label>VISION5 Product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Timolol</intervention_name>
    <description>0.5% solution</description>
    <arm_group_label>Timolol 0.5% + Placebo VISION5 Product</arm_group_label>
    <other_name>timoptic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo drops</intervention_name>
    <description>placebo topical eye drops</description>
    <arm_group_label>VISION5 Product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Written informed consent

          -  Primary open-angle glaucoma or ocular hypertension in both eyes

          -  Best-corrected distance vision of 20/80 or better

          -  Stable visual field

          -  corneal thickness between 490-620 micrometers

        Key Exclusion Criteria:

          -  Cup-to-disc ratio greater than 0.8

          -  significant risk of angle closure due to pupil dilation, defined as a Shaffer
             classification of less than grade 2 based on gonioscopy

          -  laser surgery for glaucoma/ocular hypertension on one or both eyes within the last 12
             months

          -  past history of corneal refractive surgery

          -  past history of any incisional surgery for glaucoma at any time

          -  corneal abnormalities that would interfere with tonometry readings

          -  current participation in an investigational drug or device study or participation in
             such a study within 30 days of screening

          -  Inability to accurately evaluate the retina
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James D Brandt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gary A Walker, PhD</last_name>
    <phone>650-325-2050</phone>
    <email>gwalker@forsightv5.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne Rubin</last_name>
    <phone>650-325-2050</phone>
    <email>arubin@forsightv5.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UC Davis Dept of Ophthalmology &amp; Vision Science</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James Brandt, MD</last_name>
      <phone>916-734-6969</phone>
      <email>jdbrandt@ucdavis.com</email>
    </contact>
    <investigator>
      <last_name>James Brandt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 20, 2014</lastchanged_date>
  <firstreceived_date>July 31, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Glaucoma</keyword>
  <keyword>Primary Open-Angle Glaucoma</keyword>
  <keyword>Ocular Hypertension</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Timolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
